Covance Inc. (NYSE:CVD), a provider of drug development services, today announced that its clinical pharmacology services were recognized for outstanding customer service by Eli Lilly and Company.
Covance Recognized for Outstanding
Customer Service by Eli Lilly and Company
-Covance Clinical Research Unit in Leeds receives Lilly's 2008 Global Supplier Award-
PRINCETON, NJ, July 31, 2008 - Covance Inc. (NYSE:CVD), a leading provider of drug development services, today announced that its clinical pharmacology services were recognized for outstanding customer service by Eli Lilly and Company. Covance's clinical research unit based in Leeds, UK received Lilly's 2008 Global Supplier Award, which acknowledges and encourages the contributions of key suppliers that contribute the best in innovation and technology towards Lilly's success. Covance is one of a select group of suppliers to Lilly that has demonstrated its commitment to helping the company meet its corporate objectives. Covance was judged by a committee of Lilly representatives on criteria including supplier relationship management, quality, speed, service, cost reduction, and supplier diversity. "We are honored to receive such a high level of recognition from one of the world's most prominent pharmaceutical companies," said Mary Westrick, Covance Global Vice President and General Manager of Clinical Pharmacology. "Covance is proud that our pharmaceutical clients consider us integral partners in their important development of new therapies and cures." Covance's clinical pharmacology service offering evaluates the safety and efficacy of potential new drugs in humans, including the conduct of first-in-human trials. Covance has pioneered many of the specialized services in its diversified portfolio of drug development services and that uniquely positions the company as a valued partner in helping to progress compounds from preclinical to proof-of-concept studies.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and greater than 9,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. Covance and the Covance are registered service marks of Covance in the United States and other countries.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.